loading

Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten

pulisher
08:52 AM

Recent Insider Activity Suggests Potential Gains for Crinetics Pharmaceuticals Inc (CRNX) - knoxdaily.com

08:52 AM
pulisher
Apr 28, 2025

LPL Financial LLC Acquires 1,162 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 28, 2025
pulisher
Apr 25, 2025

Market Watch Highlights: Crinetics Pharmaceuticals Inc (CRNX) Ends on an Upturn Note at 33.39 - DWinneX

Apr 25, 2025
pulisher
Apr 25, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Boosted by Envestnet Asset Management Inc. - Defense World

Apr 25, 2025
pulisher
Apr 23, 2025

Are Crinetics Pharmaceuticals Inc (CRNX) shares a good deal now? - uspostnews.com

Apr 23, 2025
pulisher
Apr 22, 2025

CRNX stock touches 52-week low at $35.47 amid market shifts - MSN

Apr 22, 2025
pulisher
Apr 22, 2025

Crinetics Pharmaceuticals patents new SSTR3 agonists - BioWorld MedTech

Apr 22, 2025
pulisher
Apr 21, 2025

Wells Fargo & Company MN Increases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 21, 2025
pulisher
Apr 21, 2025

Invesco Ltd. Acquires 42,954 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 21, 2025
pulisher
Apr 20, 2025

Russell Investments Group Ltd. Sells 43,501 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 20, 2025
pulisher
Apr 17, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Affinity Asset Advisors LLC - MarketBeat

Apr 17, 2025
pulisher
Apr 14, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by Alliancebernstein L.P. - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

JPMorgan Chase & Co. Has $13.78 Million Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 | CRNX Stock News - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times

Apr 11, 2025
pulisher
Apr 11, 2025

Key Investor Alert: Crinetics Sets Date for Crucial Q1 2025 Financial Results - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Acromegaly Pipeline 2025: Detailed Clinical Trials - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 10, 2025
pulisher
Apr 07, 2025

Stock Surge: Crinetics Pharmaceuticals Inc (CRNX) Closes at 26.89, Marking a -6.86 Increase/Decrease - DWinneX

Apr 07, 2025
pulisher
Apr 05, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Sei Investments Co. - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA - Seeking Alpha

Apr 02, 2025
pulisher
Mar 31, 2025

CRNX stock touches 52-week low at $31.81 amid market challenges - Investing.com

Mar 31, 2025
pulisher
Mar 27, 2025

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: First Oral Acromegaly Drug Hits Major EU Milestone with Dual Regulatory Wins - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Crinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by Stifel Nicolaus - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

This Clearway Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Mar 25, 2025
pulisher
Mar 25, 2025

Stifel Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Buy Recommendation - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Taking a Closer Look At Crinetics Pharmaceuticals Inc (CRNX) Following Its Recent Trade - knoxdaily.com

Mar 25, 2025
pulisher
Mar 24, 2025

Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR.com

Mar 24, 2025
pulisher
Mar 24, 2025

(CRNX) Trading Report - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Sells 13,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Proficio Capital Partners LLC Purchases Shares of 14,674 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock By Investing.com - Investing.com Australia

Mar 22, 2025
pulisher
Mar 22, 2025

Zurcher Kantonalbank Zurich Cantonalbank Purchases 2,970 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - The AM Reporter

Mar 22, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Stock: Executives Sell Shares Amid Analyst Optimism - sharewise.com

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals’ chief med and dev officer sells $86,020 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 By Investing.com - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals COO Jeff Knight sells $244,963 in stock - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals CEO Richard Struthers sells shares worth $592,016 - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Crinetics Pharmaceuticals chief scientific officer sells $197,352 in stock - Investing.com

Mar 21, 2025
pulisher
Mar 19, 2025

CRNX News Today | Why did Crinetics Pharmaceuticals stock go down today? - MarketBeat

Mar 19, 2025
pulisher
Mar 19, 2025

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Mar 19, 2025
$20.99
price up icon 1.91%
$71.40
price down icon 0.28%
$32.90
price up icon 0.11%
$23.21
price down icon 1.78%
$104.43
price up icon 0.23%
biotechnology ONC
$263.58
price up icon 5.77%
Kapitalisierung:     |  Volumen (24h):